Brain Amyloid Imaging for Alzheimer's Disease

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial uses a special brain scan to see harmful buildups in the brain. It targets both healthy people and those with brain diseases to understand how well the scan works.

Research Team

Val Lowe, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for people aged 30-100 with various forms of dementia, including Alzheimer's and Lewy Body Disease, who are part of the Mayo Clinic aging or neurodegenerative studies. It excludes pregnant or breastfeeding women, those unable to lie still for scans, claustrophobic individuals, and anyone with MRI safety risks like pacemakers.

Inclusion Criteria

You have already had or are planning to have neurological tests at the Mayo Clinic.

I am between 30 and 100 years old.

Exclusion Criteria

Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.

I cannot stay still lying down for 10 minutes.

I am not pregnant and can stop breastfeeding for 24 hours.

Treatment Details

Interventions

• F-18 FDG (Radiopharmaceutical)
• Pittsburgh Compound B (C-11 PiB) (Radiopharmaceutical)
• Tau (18-F-AV-1451) (Radiopharmaceutical)

Trial Overview The study tests imaging agents (Pittsburgh Compound B, F-18 FDG, Tau) using PET scans to track amyloid plaque buildup in the brain over time and its link to changes in clinical status among aging individuals.

Participant Groups

Group I: PiB PET, FDG PET, Tau PET Experimental Treatment 3 Interventions

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+